Search - tctmd.com

Displaying 1 - 20 of 61

Sort: Relevancy | Date

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

News Conference News ACC 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

Michael O'Riordan

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

Even When Nearby, Public AEDs Get Little Use in OHCA

L.A. McKeown

March 28, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

L.A. McKeown

March 10, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

Caitlin E. Cox

March 05, 2023

News Conference News ACC 2023

NUDGE-FLU: Emails May Help Increase Flu Vaccination in Elderly

L.A. McKeown

March 05, 2023

Advertisement

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

What’s Going to Be Hot at ACC 2026

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Telemedicine Strategy After MI Scores a Win in TELE-ACS

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Even When Nearby, Public AEDs Get Little Use in OHCA

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS

NUDGE-FLU: Emails May Help Increase Flu Vaccination in Elderly

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content